Little House Capital LLC Decreases Stock Holdings in Abbott Laboratories $ABT

Little House Capital LLC decreased its position in Abbott Laboratories (NYSE:ABT) by 48.7% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 7,557 shares of the healthcare product maker’s stock after selling 7,187 shares during the quarter. Little House Capital LLC’s holdings in Abbott Laboratories were worth $1,028,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of the company. FF Advisors LLC increased its position in shares of Abbott Laboratories by 4.3% in the second quarter. FF Advisors LLC now owns 1,904 shares of the healthcare product maker’s stock valued at $259,000 after acquiring an additional 79 shares during the period. Everpar Advisors LLC increased its position in shares of Abbott Laboratories by 11.0% in the second quarter. Everpar Advisors LLC now owns 4,423 shares of the healthcare product maker’s stock valued at $602,000 after acquiring an additional 437 shares during the period. Arlington Trust Co LLC boosted its stake in shares of Abbott Laboratories by 9.1% during the 2nd quarter. Arlington Trust Co LLC now owns 11,940 shares of the healthcare product maker’s stock valued at $1,624,000 after purchasing an additional 1,000 shares in the last quarter. Persium Advisors LLC boosted its stake in shares of Abbott Laboratories by 3.8% during the 2nd quarter. Persium Advisors LLC now owns 5,946 shares of the healthcare product maker’s stock valued at $809,000 after purchasing an additional 218 shares in the last quarter. Finally, Webster Bank N. A. boosted its stake in shares of Abbott Laboratories by 1.2% during the 2nd quarter. Webster Bank N. A. now owns 11,784 shares of the healthcare product maker’s stock valued at $1,603,000 after purchasing an additional 141 shares in the last quarter. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Insider Buying and Selling

In other Abbott Laboratories news, CFO Philip P. Boudreau sold 5,550 shares of the firm’s stock in a transaction dated Friday, August 8th. The shares were sold at an average price of $134.55, for a total transaction of $746,752.50. Following the transaction, the chief financial officer owned 51,003 shares of the company’s stock, valued at approximately $6,862,453.65. This trade represents a 9.81% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 0.46% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the stock. Mizuho lifted their target price on shares of Abbott Laboratories from $130.00 to $140.00 and gave the company a “neutral” rating in a research note on Wednesday, July 16th. Leerink Partnrs raised shares of Abbott Laboratories to a “hold” rating in a research note on Monday, June 16th. BTIG Research cut their target price on shares of Abbott Laboratories from $148.00 to $145.00 and set a “buy” rating on the stock in a research note on Friday, July 18th. Wells Fargo & Company cut their target price on shares of Abbott Laboratories from $147.00 to $142.00 and set an “overweight” rating on the stock in a research note on Friday, July 18th. Finally, Jefferies Financial Group raised shares of Abbott Laboratories from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $143.00 to $145.00 in a research note on Friday, July 18th. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and four have issued a Hold rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $144.47.

Abbott Laboratories Price Performance

ABT stock opened at $131.40 on Tuesday. Abbott Laboratories has a 52 week low of $110.86 and a 52 week high of $141.23. The company has a quick ratio of 1.30, a current ratio of 1.82 and a debt-to-equity ratio of 0.25. The company has a fifty day simple moving average of $130.36 and a two-hundred day simple moving average of $131.21. The firm has a market capitalization of $228.70 billion, a P/E ratio of 16.47, a price-to-earnings-growth ratio of 2.54 and a beta of 0.69.

Abbott Laboratories (NYSE:ABT) last announced its earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 earnings per share for the quarter, meeting the consensus estimate of $1.26. Abbott Laboratories had a net margin of 32.43% and a return on equity of 18.32%. The business had revenue of $11.14 billion for the quarter, compared to the consensus estimate of $11.01 billion. During the same quarter in the prior year, the firm posted $1.14 earnings per share. The business’s revenue for the quarter was up 7.4% on a year-over-year basis. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. Analysts anticipate that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.